Mechanism

How it works

Gonadorelin binds to GnRH receptors (GnRH-R) on pituitary gonadotroph cells, activating Gq/11-coupled signaling and triggering phospholipase C-mediated IP3 and DAG production, which raises intracellular calcium and activates protein kinase C. This cascade promotes synthesis and pulsatile secretion of LH and FSH from the anterior pituitary. LH then acts on Leydig cells in the testes to stimulate testosterone synthesis via the cAMP-PKA pathway, while FSH acts on Sertoli cells to maintain spermatogenesis.

Reported in research

Benefits

Preserves endogenous testosterone production and testicular volume during exogenous androgen use
Stimulates LH and FSH release to support fertility and spermatogenesis
Supports recovery of the hypothalamic-pituitary-gonadal (HPG) axis post-cycle
Used diagnostically to assess pituitary gonadotroph function and reserve

Context, not a prescription

Dosing

Typical range: 100–250 mcg 2–3x per week (research/off-label context); clinical diagnostic dose 100 mcg IV/subq single bolus (Subcutaneous, Intramuscular, Nasal)
Cycle length: Concurrent with androgen cycle or 4–8 weeks post-cycle
Half-life: ~2–4 minutes (IV); ~30–60 minutes (subq)

Safety

Side effects & contraindications

Possible side effects

Injection site redness, swelling, or mild pain
Nausea and abdominal discomfort
Headache
Flushing or lightheadedness after injection
Ovarian hyperstimulation syndrome (OHSS) in women — rare but serious
Desensitization/receptor downregulation with continuous (non-pulsatile) dosing

Contraindications

Known hypersensitivity or allergy to GnRH or any of its analogs
Hormone-sensitive cancers (e.g., prostate cancer, breast cancer) — continuous dosing may initially flare
Pregnancy (may stimulate uterine contractions)
Polycystic ovary syndrome (PCOS) with high endogenous LH — risk of OHSS
Pituitary adenoma secreting gonadotropins

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Users may notice maintenance of testicular size, improved libido and mood compared to running exogenous testosterone alone, and fewer symptoms of hormonal suppression. In a fertility context, improved sperm parameters may be observed after several weeks.

How it works

Think of your hormone system like a chain of command in a company. Your hypothalamus (the CEO) sends a memo (gonadorelin) to the pituitary (the manager), who then issues orders to the testes or ovaries (the workers) to produce testosterone. Gonadorelin is like sending that memo manually so the workers stay active even when the CEO is distracted.

After injection, gonadorelin travels through your bloodstream to the pituitary gland and briefly activates receptors there, causing a burst of LH and FSH release. These hormones then travel to the gonads, stimulating testosterone production and sperm or egg development. Because it acts quickly and leaves the body fast, it mimics the natural pulsatile pattern your body normally uses.

What to expect

LH and FSH levels begin rising within 15–30 minutes of injection. Noticeable effects on testicular function and testosterone levels may take 1–4 weeks of consistent use.

Week 1: Pituitary begins responding to gonadorelin injections; LH and FSH pulse after each dose. You may not feel dramatic changes yet, but hormone signaling is being maintained.
Weeks 2–4: Consistent stimulation helps preserve testicular function and endogenous testosterone signaling. Users often notice better mood and libido compared to not using it during an androgen cycle.
Weeks 4–8: Continued use supports HPG axis health. Post-cycle, LH and FSH recovery is faster. Testicular volume is better preserved compared to no gonadorelin use.

Good to know

Use in a pulsatile, intermittent fashion (e.g., 2–3x per week) rather than continuous daily dosing to avoid receptor desensitization
Start with a lower dose (100 mcg) to assess tolerance before increasing
Always reconstitute with bacteriostatic water and use proper sterile technique

Staying safe

Mild redness or soreness at the injection site
Brief nausea or stomach discomfort after dosing
Occasional headache or flushing

Avoid if you have:

Women who are pregnant or trying to conceive without medical supervision
People with known hormone-sensitive tumors
Those with a history of allergic reactions to GnRH-based medications

Overview

Physiological changes include maintained intratesticular testosterone concentrations (ITT), preservation of Leydig and Sertoli cell populations, continued spermatogenesis (versus spermatogenic arrest with TRT alone), maintained testicular volume (measured by orchidometry), and — in hypogonadal patients not on exogenous androgens — restoration of serum testosterone to eugonadal range. In HPG-axis recovery protocols post-anabolic cycle, gonadorelin accelerates restoration of endogenous LH pulsatility and testicular steroidogenesis.

How it works

The GnRH receptor behaves like a Morse code receiver: it requires a rhythmic on-off signal to properly transmit messages. A continuous, uninterrupted signal overwhelms the receiver and causes it to shut off entirely — this is why GnRH agonists like leuprolide, given continuously, cause chemical castration, while pulsatile gonadorelin administration stimulates the gonadotroph axis.

Following subcutaneous administration, gonadorelin acetate is absorbed with a Tmax of approximately 20–40 minutes and a subcutaneous half-life of roughly 30–60 minutes (versus ~2–4 minutes IV). It is rapidly metabolized by endopeptidases and tissue-bound proteases, particularly at the Tyr5-Gly6 and Pro9-Gly10 bonds. Binding to GnRH-R on gonadotrophs initiates PKC-mediated phosphorylation cascades that upregulate LHβ and FSHβ subunit gene transcription via AP-1 and SF-1 transcription factors. LH pulses downstream drive Leydig cell StAR protein expression and CYP17A1/CYP11A1-mediated testosterone biosynthesis. FSH acts on Sertoli cells via cAMP/PKA pathways to support androgen-binding protein (ABP) secretion and spermatogenesis. With exogenous androgen use, Leydig cell atrophy and reduced intratesticular testosterone (ITT) occur; gonadorelin counteracts this by maintaining endogenous LH pulses.

Onset & timeline

Serum LH elevates within 15–30 minutes post-injection; peak LH occurs at approximately 30–60 minutes (subq route). FSH response is blunted and slower. Leydig cell response to elevated LH results in detectable testosterone rise within 2–4 hours. Clinically meaningful preservation of testicular volume and spermatogenesis requires 4–8 weeks of consistent pulsatile administration.

Days 1–3: Acute GnRH-R occupancy triggers rapid LH and FSH exocytosis (measurable within 30 minutes). Serum testosterone rises transiently post-injection. Receptor upregulation may paradoxically occur with initial low-dose pulsatile exposure.
Weeks 1–2: Repeated pulsatile GnRH-R stimulation maintains gonadotroph sensitivity. Intratesticular testosterone (ITT) concentrations are preserved compared to exogenous androgen use alone. Leydig cell hypertrophy begins to reverse if previously atrophied from prior androgen suppression.
Weeks 2–8: Sustained pulsatile LH stimulation restores full Leydig cell steroidogenic capacity. Spermatogenesis is maintained or partially restored (complete spermatogenic cycle is ~74 days). Post-cycle, LH pulsatility recovery is significantly accelerated vs. no gonadorelin use. Testicular volume is measurably preserved by orchidometry.

Getting the most from it

Maintain strict pulsatile dosing intervals (minimum every 48 hours) to prevent receptor downregulation and paradoxical suppression
Monitor serum LH, FSH, and total testosterone at 4-week intervals to confirm HPG axis responsiveness
Reconstitute with bacteriostatic water and store at 2–8°C; discard reconstituted vials after 48 hours to prevent degradation
In women, monitor follicular development with ultrasound if using for fertility stimulation to prevent OHSS
Rotate injection sites to reduce local tissue desensitization and fibrosis

Common side effects

Injection site reactions (erythema, induration, pruritus) — reported in ~10–15% of users
Transient nausea, abdominal cramping within 30 minutes of injection — typically mild
Headache and flushing from acute LH/FSH surge — usually resolves within 1–2 hours
Receptor desensitization and paradoxical hypogonadism if dosed continuously rather than pulsatilely

Mechanism of action

Gonadorelin acetate is a synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that acts as a full agonist at the GnRH receptor (GnRH-R), a seven-transmembrane Gq/11-protein-coupled receptor expressed on anterior pituitary gonadotrophs. Receptor binding activates phospholipase C-β, generating IP3 and DAG from PIP2 hydrolysis. IP3 triggers endoplasmic reticulum calcium release while DAG activates PKC, collectively inducing exocytosis of LH and FSH vesicles. Critically, endogenous GnRH — and exogenous gonadorelin when used intermittently — acts in a pulsatile manner (approximately every 60–120 minutes physiologically). Sustained, continuous GnRH-R stimulation leads to receptor internalization, uncoupling of G-protein signaling (homologous desensitization), and paradoxical gonadotropin suppression — the pharmacological basis for GnRH agonist use in prostate cancer and endometriosis.

Following subcutaneous administration, gonadorelin acetate is absorbed with a Tmax of approximately 20–40 minutes and a subcutaneous half-life of roughly 30–60 minutes (versus ~2–4 minutes IV). It is rapidly metabolized by endopeptidases and tissue-bound proteases, particularly at the Tyr5-Gly6 and Pro9-Gly10 bonds. Binding to GnRH-R on gonadotrophs initiates PKC-mediated phosphorylation cascades that upregulate LHβ and FSHβ subunit gene transcription via AP-1 and SF-1 transcription factors. LH pulses downstream drive Leydig cell StAR protein expression and CYP17A1/CYP11A1-mediated testosterone biosynthesis. FSH acts on Sertoli cells via cAMP/PKA pathways to support androgen-binding protein (ABP) secretion and spermatogenesis. With exogenous androgen use, Leydig cell atrophy and reduced intratesticular testosterone (ITT) occur; gonadorelin counteracts this by maintaining endogenous LH pulses.

Pharmacodynamics

Serum LH elevates within 15–30 minutes post-injection; peak LH occurs at approximately 30–60 minutes (subq route). FSH response is blunted and slower. Leydig cell response to elevated LH results in detectable testosterone rise within 2–4 hours. Clinically meaningful preservation of testicular volume and spermatogenesis requires 4–8 weeks of consistent pulsatile administration.

Physiological changes include maintained intratesticular testosterone concentrations (ITT), preservation of Leydig and Sertoli cell populations, continued spermatogenesis (versus spermatogenic arrest with TRT alone), maintained testicular volume (measured by orchidometry), and — in hypogonadal patients not on exogenous androgens — restoration of serum testosterone to eugonadal range. In HPG-axis recovery protocols post-anabolic cycle, gonadorelin accelerates restoration of endogenous LH pulsatility and testicular steroidogenesis.

Timeline

Days 1–3: Acute GnRH-R occupancy triggers rapid LH and FSH exocytosis (measurable within 30 minutes). Serum testosterone rises transiently post-injection. Receptor upregulation may paradoxically occur with initial low-dose pulsatile exposure.
Weeks 1–2: Repeated pulsatile GnRH-R stimulation maintains gonadotroph sensitivity. Intratesticular testosterone (ITT) concentrations are preserved compared to exogenous androgen use alone. Leydig cell hypertrophy begins to reverse if previously atrophied from prior androgen suppression.
Weeks 2–8: Sustained pulsatile LH stimulation restores full Leydig cell steroidogenic capacity. Spermatogenesis is maintained or partially restored (complete spermatogenic cycle is ~74 days). Post-cycle, LH pulsatility recovery is significantly accelerated vs. no gonadorelin use. Testicular volume is measurably preserved by orchidometry.

Comparisons

Gonadorelin Acetate — effectiveness High, safety Good, cost $$, Medium to use
HCG (Human Chorionic Gonadotropin) — effectiveness High, safety Good, cost $$$, Medium to use
Kisspeptin-10 — effectiveness Moderate, safety Good, cost $$$, Low to use
Enclomiphene Citrate — effectiveness Moderate, safety Moderate, cost $$, High to use

Adverse effects

Common:

Injection site reactions (erythema, induration, pruritus) — reported in ~10–15% of users
Transient nausea, abdominal cramping within 30 minutes of injection — typically mild
Headache and flushing from acute LH/FSH surge — usually resolves within 1–2 hours
Receptor desensitization and paradoxical hypogonadism if dosed continuously rather than pulsatilely

Rare:

Anaphylaxis or severe hypersensitivity reactions (<0.1% incidence; more common with repeated exposure)
Ovarian hyperstimulation syndrome (OHSS) in women with polycystic or highly responsive ovaries — potentially serious
Transient gynecomastia or water retention from FSH-mediated aromatase upregulation in some contexts

Contraindications & risk mitigation

Contraindicated in:

Patients with androgen-sensitive malignancies (prostate carcinoma, breast cancer) where initial testosterone flare may be harmful — without concurrent anti-androgen coverage
Women with PCOS or elevated baseline LH/estradiol due to OHSS risk
Patients with pituitary tumors (gonadotroph adenomas) secreting excess LH/FSH
Individuals with prior confirmed anaphylaxis to GnRH analogs
Pregnant women (uterotonic risk)

Maintain strict pulsatile dosing intervals (minimum every 48 hours) to prevent receptor downregulation and paradoxical suppression
Monitor serum LH, FSH, and total testosterone at 4-week intervals to confirm HPG axis responsiveness
Reconstitute with bacteriostatic water and store at 2–8°C; discard reconstituted vials after 48 hours to prevent degradation
In women, monitor follicular development with ultrasound if using for fertility stimulation to prevent OHSS
Rotate injection sites to reduce local tissue desensitization and fibrosis

Qué hace

Users may notice maintenance of testicular size, improved libido and mood compared to running exogenous testosterone alone, and fewer symptoms of hormonal suppression. In a fertility context, improved sperm parameters may be observed after several weeks.

Cómo funciona

Think of your hormone system like a chain of command in a company. Your hypothalamus (the CEO) sends a memo (gonadorelin) to the pituitary (the manager), who then issues orders to the testes or ovaries (the workers) to produce testosterone. Gonadorelin is like sending that memo manually so the workers stay active even when the CEO is distracted.

After injection, gonadorelin travels through your bloodstream to the pituitary gland and briefly activates receptors there, causing a burst of LH and FSH release. These hormones then travel to the gonads, stimulating testosterone production and sperm or egg development. Because it acts quickly and leaves the body fast, it mimics the natural pulsatile pattern your body normally uses.

Qué esperar

LH and FSH levels begin rising within 15–30 minutes of injection. Noticeable effects on testicular function and testosterone levels may take 1–4 weeks of consistent use.

Week 1: Pituitary begins responding to gonadorelin injections; LH and FSH pulse after each dose. You may not feel dramatic changes yet, but hormone signaling is being maintained.
Weeks 2–4: Consistent stimulation helps preserve testicular function and endogenous testosterone signaling. Users often notice better mood and libido compared to not using it during an androgen cycle.
Weeks 4–8: Continued use supports HPG axis health. Post-cycle, LH and FSH recovery is faster. Testicular volume is better preserved compared to no gonadorelin use.

Bueno saber

Use in a pulsatile, intermittent fashion (e.g., 2–3x per week) rather than continuous daily dosing to avoid receptor desensitization
Start with a lower dose (100 mcg) to assess tolerance before increasing
Always reconstitute with bacteriostatic water and use proper sterile technique

Manteniéndose seguro

Mild redness or soreness at the injection site
Brief nausea or stomach discomfort after dosing
Occasional headache or flushing

Evitar si tienes:

Women who are pregnant or trying to conceive without medical supervision
People with known hormone-sensitive tumors
Those with a history of allergic reactions to GnRH-based medications

Descripción general

Physiological changes include maintained intratesticular testosterone concentrations (ITT), preservation of Leydig and Sertoli cell populations, continued spermatogenesis (versus spermatogenic arrest with TRT alone), maintained testicular volume (measured by orchidometry), and — in hypogonadal patients not on exogenous androgens — restoration of serum testosterone to eugonadal range. In HPG-axis recovery protocols post-anabolic cycle, gonadorelin accelerates restoration of endogenous LH pulsatility and testicular steroidogenesis.

Cómo funciona

The GnRH receptor behaves like a Morse code receiver: it requires a rhythmic on-off signal to properly transmit messages. A continuous, uninterrupted signal overwhelms the receiver and causes it to shut off entirely — this is why GnRH agonists like leuprolide, given continuously, cause chemical castration, while pulsatile gonadorelin administration stimulates the gonadotroph axis.

Following subcutaneous administration, gonadorelin acetate is absorbed with a Tmax of approximately 20–40 minutes and a subcutaneous half-life of roughly 30–60 minutes (versus ~2–4 minutes IV). It is rapidly metabolized by endopeptidases and tissue-bound proteases, particularly at the Tyr5-Gly6 and Pro9-Gly10 bonds. Binding to GnRH-R on gonadotrophs initiates PKC-mediated phosphorylation cascades that upregulate LHβ and FSHβ subunit gene transcription via AP-1 and SF-1 transcription factors. LH pulses downstream drive Leydig cell StAR protein expression and CYP17A1/CYP11A1-mediated testosterone biosynthesis. FSH acts on Sertoli cells via cAMP/PKA pathways to support androgen-binding protein (ABP) secretion and spermatogenesis. With exogenous androgen use, Leydig cell atrophy and reduced intratesticular testosterone (ITT) occur; gonadorelin counteracts this by maintaining endogenous LH pulses.

Inicio y cronología

Serum LH elevates within 15–30 minutes post-injection; peak LH occurs at approximately 30–60 minutes (subq route). FSH response is blunted and slower. Leydig cell response to elevated LH results in detectable testosterone rise within 2–4 hours. Clinically meaningful preservation of testicular volume and spermatogenesis requires 4–8 weeks of consistent pulsatile administration.

Days 1–3: Acute GnRH-R occupancy triggers rapid LH and FSH exocytosis (measurable within 30 minutes). Serum testosterone rises transiently post-injection. Receptor upregulation may paradoxically occur with initial low-dose pulsatile exposure.
Weeks 1–2: Repeated pulsatile GnRH-R stimulation maintains gonadotroph sensitivity. Intratesticular testosterone (ITT) concentrations are preserved compared to exogenous androgen use alone. Leydig cell hypertrophy begins to reverse if previously atrophied from prior androgen suppression.
Weeks 2–8: Sustained pulsatile LH stimulation restores full Leydig cell steroidogenic capacity. Spermatogenesis is maintained or partially restored (complete spermatogenic cycle is ~74 days). Post-cycle, LH pulsatility recovery is significantly accelerated vs. no gonadorelin use. Testicular volume is measurably preserved by orchidometry.

Cómo aprovecharlo al máximo

Maintain strict pulsatile dosing intervals (minimum every 48 hours) to prevent receptor downregulation and paradoxical suppression
Monitor serum LH, FSH, and total testosterone at 4-week intervals to confirm HPG axis responsiveness
Reconstitute with bacteriostatic water and store at 2–8°C; discard reconstituted vials after 48 hours to prevent degradation
In women, monitor follicular development with ultrasound if using for fertility stimulation to prevent OHSS
Rotate injection sites to reduce local tissue desensitization and fibrosis

Efectos secundarios comunes

Injection site reactions (erythema, induration, pruritus) — reported in ~10–15% of users
Transient nausea, abdominal cramping within 30 minutes of injection — typically mild
Headache and flushing from acute LH/FSH surge — usually resolves within 1–2 hours
Receptor desensitization and paradoxical hypogonadism if dosed continuously rather than pulsatilely

Mecanismo de acción

Gonadorelin acetate is a synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that acts as a full agonist at the GnRH receptor (GnRH-R), a seven-transmembrane Gq/11-protein-coupled receptor expressed on anterior pituitary gonadotrophs. Receptor binding activates phospholipase C-β, generating IP3 and DAG from PIP2 hydrolysis. IP3 triggers endoplasmic reticulum calcium release while DAG activates PKC, collectively inducing exocytosis of LH and FSH vesicles. Critically, endogenous GnRH — and exogenous gonadorelin when used intermittently — acts in a pulsatile manner (approximately every 60–120 minutes physiologically). Sustained, continuous GnRH-R stimulation leads to receptor internalization, uncoupling of G-protein signaling (homologous desensitization), and paradoxical gonadotropin suppression — the pharmacological basis for GnRH agonist use in prostate cancer and endometriosis.

Following subcutaneous administration, gonadorelin acetate is absorbed with a Tmax of approximately 20–40 minutes and a subcutaneous half-life of roughly 30–60 minutes (versus ~2–4 minutes IV). It is rapidly metabolized by endopeptidases and tissue-bound proteases, particularly at the Tyr5-Gly6 and Pro9-Gly10 bonds. Binding to GnRH-R on gonadotrophs initiates PKC-mediated phosphorylation cascades that upregulate LHβ and FSHβ subunit gene transcription via AP-1 and SF-1 transcription factors. LH pulses downstream drive Leydig cell StAR protein expression and CYP17A1/CYP11A1-mediated testosterone biosynthesis. FSH acts on Sertoli cells via cAMP/PKA pathways to support androgen-binding protein (ABP) secretion and spermatogenesis. With exogenous androgen use, Leydig cell atrophy and reduced intratesticular testosterone (ITT) occur; gonadorelin counteracts this by maintaining endogenous LH pulses.

Farmacodinamia

Serum LH elevates within 15–30 minutes post-injection; peak LH occurs at approximately 30–60 minutes (subq route). FSH response is blunted and slower. Leydig cell response to elevated LH results in detectable testosterone rise within 2–4 hours. Clinically meaningful preservation of testicular volume and spermatogenesis requires 4–8 weeks of consistent pulsatile administration.

Physiological changes include maintained intratesticular testosterone concentrations (ITT), preservation of Leydig and Sertoli cell populations, continued spermatogenesis (versus spermatogenic arrest with TRT alone), maintained testicular volume (measured by orchidometry), and — in hypogonadal patients not on exogenous androgens — restoration of serum testosterone to eugonadal range. In HPG-axis recovery protocols post-anabolic cycle, gonadorelin accelerates restoration of endogenous LH pulsatility and testicular steroidogenesis.

Cronología

Days 1–3: Acute GnRH-R occupancy triggers rapid LH and FSH exocytosis (measurable within 30 minutes). Serum testosterone rises transiently post-injection. Receptor upregulation may paradoxically occur with initial low-dose pulsatile exposure.
Weeks 1–2: Repeated pulsatile GnRH-R stimulation maintains gonadotroph sensitivity. Intratesticular testosterone (ITT) concentrations are preserved compared to exogenous androgen use alone. Leydig cell hypertrophy begins to reverse if previously atrophied from prior androgen suppression.
Weeks 2–8: Sustained pulsatile LH stimulation restores full Leydig cell steroidogenic capacity. Spermatogenesis is maintained or partially restored (complete spermatogenic cycle is ~74 days). Post-cycle, LH pulsatility recovery is significantly accelerated vs. no gonadorelin use. Testicular volume is measurably preserved by orchidometry.

Comparaciones

Gonadorelin Acetate — efectividad High, seguridad Good, costo $$, Medium de usar
HCG (Human Chorionic Gonadotropin) — efectividad High, seguridad Good, costo $$$, Medium de usar
Kisspeptin-10 — efectividad Moderate, seguridad Good, costo $$$, Low de usar
Enclomiphene Citrate — efectividad Moderate, seguridad Moderate, costo $$, High de usar

Efectos adversos

Comunes:

Injection site reactions (erythema, induration, pruritus) — reported in ~10–15% of users
Transient nausea, abdominal cramping within 30 minutes of injection — typically mild
Headache and flushing from acute LH/FSH surge — usually resolves within 1–2 hours
Receptor desensitization and paradoxical hypogonadism if dosed continuously rather than pulsatilely

Raros:

Anaphylaxis or severe hypersensitivity reactions (<0.1% incidence; more common with repeated exposure)
Ovarian hyperstimulation syndrome (OHSS) in women with polycystic or highly responsive ovaries — potentially serious
Transient gynecomastia or water retention from FSH-mediated aromatase upregulation in some contexts

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Patients with androgen-sensitive malignancies (prostate carcinoma, breast cancer) where initial testosterone flare may be harmful — without concurrent anti-androgen coverage
Women with PCOS or elevated baseline LH/estradiol due to OHSS risk
Patients with pituitary tumors (gonadotroph adenomas) secreting excess LH/FSH
Individuals with prior confirmed anaphylaxis to GnRH analogs
Pregnant women (uterotonic risk)

Maintain strict pulsatile dosing intervals (minimum every 48 hours) to prevent receptor downregulation and paradoxical suppression
Monitor serum LH, FSH, and total testosterone at 4-week intervals to confirm HPG axis responsiveness
Reconstitute with bacteriostatic water and store at 2–8°C; discard reconstituted vials after 48 hours to prevent degradation
In women, monitor follicular development with ultrasound if using for fertility stimulation to prevent OHSS
Rotate injection sites to reduce local tissue desensitization and fibrosis

Reference data

Specifications

Molecular formula: C55H75N17O13 · xC2H4O2 (acetate salt)
Molecular weight: 1182.31 g/mol (free base); ~1242 g/mol as acetate salt (approximate)
Half-life: ~2–4 minutes (IV); ~30–60 minutes (subq)
Route: Subcutaneous, Intramuscular, Nasal
Cycle length: Concurrent with androgen cycle or 4–8 weeks post-cycle
Storage: Store lyophilized powder at 2–8°C (refrigerated), protected from light. Once reconstituted, use within 24–48 hours if refrigerated. Do not freeze reconstituted solution. Keep away from heat and humidity.
Legal status: FDA-approved prescription drug (Factrel, Lutrepulse) in the United States; available as a research peptide in many jurisdictions without prescription; classified as a prescription-only medicine in the EU and UK.

FAQ

Common questions

What is the mechanistic distinction between gonadorelin and GnRH agonists like leuprolide?

Both are GnRH-R full agonists, but gonadorelin has a very short half-life (~2–4 min IV, ~30–60 min subq) enabling pulsatile receptor activation followed by receptor recovery — mimicking physiological GnRH. Leuprolide and other synthetic GnRH agonists have half-lives of hours to days (especially depot formulations), causing continuous GnRH-R occupancy, receptor internalization, downregulation of Gq-protein coupling, and ultimately gonadotropin suppression. This is the basis for their anti-androgenic clinical use in prostate cancer and endometriosis.

How does gonadorelin compare to HCG for testicular preservation during TRT?

HCG directly mimics LH by binding LH/hCG receptors on Leydig cells, bypassing the pituitary entirely. Gonadorelin stimulates the entire HPG axis including the pituitary, maintaining both LH and FSH. FSH is critical for spermatogenesis, which HCG does not adequately stimulate alone. For fertility preservation, gonadorelin may be superior; for pure testicular volume maintenance, both are effective. Some clinicians combine low-dose HCG with gonadorelin for comprehensive HPG axis support.

What is the optimal dosing frequency to prevent desensitization?

Physiological GnRH pulses occur every 60–120 minutes, but this is impractical to replicate exogenously. Research protocols and clinical experience suggest 2–3x weekly subq injections of 100–250 mcg represent a pragmatic compromise maintaining receptor sensitivity. Daily subq dosing at low concentrations may also be viable. Continuous infusion or very high-frequency daily injections risk receptor internalization and axis suppression, analogous to GnRH agonist pharmacology.

What is the evidence level?

This compound is classified as Clinical evidence. Randomized controlled trial data in humans exists and supports use in specific contexts.

Research

Research & sources

Clinical evidence

Current evidence for Gonadorelin Acetate is rated as Clinical evidence. Human clinical evidence supports the reported effects.

1. Pulsatile GnRH therapy to induce fertility in a man with hypogonadotropic hypogonadism (2020) — Fertility and Sterility — general review of GnRH pulsatile therapy literature
2. Millar RP et al. Gonadotropin-releasing hormone receptors (2004) — Endocrine Reviews, 25(2):235-275. DOI: 10.1210/er.2003-0002
3. Spratt DI et al. Pulsatile gonadotropin-releasing hormone administration in normal men — response to physiologic and supraphysiologic doses (1986) — Journal of Clinical Endocrinology & Metabolism, 63(5):1179-1184
4. Liu PY et al. The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations (2004) — Journal of Clinical Endocrinology & Metabolism, 89(10):4789-4796

Explore

Often discussed alongside

Human Chorionic Gonadotropin (HCG) · sexual Ipamorelin · growth